Loading…
SAB Biotherapeutics, Inc. is projected to rise to $5.10 by 2027, a +42% move from its current price of $3.60. SABS is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $3.47 | $3.60 | $3.73 | -0.05% |
| May 30 | $3.41 | $3.60 | $3.79 | -0.11% |
| May 31 | $3.37 | $3.59 | $3.83 | -0.16% |
| Jun 1 | $3.33 | $3.59 | $3.87 | -0.22% |
| Jun 2 | $3.30 | $3.59 | $3.90 | -0.27% |
| Jun 3 | $3.28 | $3.59 | $3.93 | -0.33% |
| Jun 4 | $3.25 | $3.59 | $3.96 | -0.38% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $3.25 | $3.59 | $3.96 | -0.38% |
| Week 2 | $3.11 | $3.57 | $4.11 | -0.76% |
| Week 3 | $3.00 | $3.56 | $4.22 | -1.13% |
| Week 4 | $2.91 | $3.55 | $4.32 | -1.51% |
| Week 5 | $2.83 | $3.53 | $4.40 | -1.88% |
| Week 6 | $2.76 | $3.52 | $4.48 | -2.26% |
| Week 7 | $2.70 | $3.51 | $4.55 | -2.63% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials.
The company operates in the Healthcare sector and was founded in 2014 with headquarters in Miami Beach, Florida.
SAB Biotherapeutics, Inc. trades under the symbol SABS and is currently priced at $3.60 per share. The company has a market cap of $275.27M and is ranked 3557 by market capitalization.
A major floor 14.3% below — a decisive break under it would weaken the trend.
The nearest floor, 3.6% below — buyers have tended to step in here.
The nearest ceiling, 14.2% above — a clean break opens room to run.
A major ceiling 27.5% above — clearing it would confirm fresh momentum.
Key SABS support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of SABS market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $3.76 | Sell | $3.73 | Sell |
| MA 10 | $3.75 | Sell | $3.74 | Sell |
| MA 20 | $3.74 | Sell | $3.75 | Sell |
| MA 50 | $3.79 | Sell | $3.79 | Sell |
| MA 100 | $3.90 | Sell | $3.74 | Sell |
| MA 200 | $3.40 | Buy | $3.49 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 45.57 | Neutral |
| Stoch RSI (14) | 8.54 | Buy |
| CCI (20) | -66.85 | Neutral |
| Williams %R (14) | -91.07 | Info |
| MACD (12,26,9) | -0.00 | Sell |
| ROC (12) | -12.41 | Sell |
| Bollinger %B (20,2) | 0.30 | Neutral |
| Stochastic %K (14) | 8.93 | Buy |
| TRIX (15) | -0.06 | Sell |
| Awesome (5,34) | -0.00 | Sell |
| Ultimate (7,14,28) | 44.56 | Neutral |
| Momentum (10) | -0.02 | Sell |
| Aroon Osc (25) | 20.00 | Buy |
| Hull MA (9) | 3.82 | Sell |
| ADX (14) | 8.23 | Neutral |
| ATR (14) | 0.14 | Info |
The near-term technical picture is bullish with a neutral RSI(14) reading of 50. The stock’s moving averages show a 50-day SMA of $3.79 and a 200-day SMA of $3.40, signaling a potential crossover dynamic. Support is indicated at $3.47 and resistance at $4.11, framing a near-term trading range.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $3.47 | $3.60 | $5.30 | 0% | Neutral | |
| $3.90 | $5.10 | $7.14 | +42% | Bullish | |
| $4.58 | $6.23 | $9.13 | +73% | Bullish | |
| $4.75 | $6.67 | $10.15 | +85% | Bullish | |
| $5.03 | $7.27 | $11.40 | +102% | Bullish | |
| $5.13 | $7.62 | $12.26 | +112% | Bullish | |
| $4.89 | $7.45 | $12.28 | +107% | Bullish | |
| $5.50 | $8.58 | $14.44 | +138% | Bullish | |
| $6.56 | $10.48 | $17.99 | +191% | Bullish | |
| $7.69 | $12.56 | $21.96 | +249% | Bullish | |
| $7.75 | $14.04 | $26.48 | +290% | Bullish | |
| $17.03 | $37.22 | $78.25 | +934% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $3.47 | $3.60 | $4.26 | +0.00% |
| June 2026 | $3.04 | $3.60 | $4.39 | +0.06% |
| July 2026 | $2.86 | $3.43 | $4.25 | -4.89% |
| August 2026 | $2.89 | $3.49 | $4.39 | +1.88% |
| September 2026 | $3.02 | $3.68 | $4.68 | +5.37% |
| October 2026 | $3.00 | $3.68 | $4.72 | -0.01% |
| November 2026 | $3.02 | $3.73 | $4.83 | +1.38% |
| December 2026 | $3.27 | $4.06 | $5.30 | +8.76% |
Click any year to see its month-by-month SABS forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, SABS is projected to trade between $3.47 and $5.30, averaging $3.60 — a potential gain of 0% from today's $3.60. Price action looks broadly range-bound.
SAB Biotherapeutics, Inc.'s 2027 outlook centres on $5.10, within a $3.90 to $7.14 range. That is up +42% on the projected 2026 average. That marks a +42% change versus current levels. Buyers look set to stay in control over this stretch.
By 2028, SABS could reach as high as $9.13, with a base case around $6.23 and support toward $4.58 — roughly +73% from $3.60. Momentum favours further upside here.
Expect SABS to range from $4.75 to $10.15 through 2029. The $6.67 average target implies a +85% move from current prices. That is up +7% on the projected 2028 average. Buyers look set to stay in control over this stretch.
The SABS price prediction for 2030 points to an average of $7.27 (low $5.03, high $11.40) — a potential gain of +102% on today's $3.60. Momentum favours further upside here.
In 2031, SABS is projected to trade between $5.13 and $12.26, averaging $7.62 — a potential gain of +112% from today's $3.60. That is up +5% on the projected 2030 average. Buyers look set to stay in control over this stretch.
SAB Biotherapeutics, Inc.'s 2032 outlook centres on $7.45, within a $4.89 to $12.28 range. That is -2% versus the projected 2031 average. That marks a +107% change versus current levels. Momentum favours further upside here.
By 2033, SABS could reach as high as $14.44, with a base case around $8.58 and support toward $5.50 — roughly +138% from $3.60. Buyers look set to stay in control over this stretch.
Expect SABS to range from $6.56 to $17.99 through 2034. The $10.48 average target implies a +191% move from current prices. That is up +22% on the projected 2033 average. Momentum favours further upside here.
The SABS price prediction for 2035 points to an average of $12.56 (low $7.69, high $21.96) — a potential gain of +249% on today's $3.60. Buyers look set to stay in control over this stretch.
In 2040, SABS is projected to trade between $7.75 and $26.48, averaging $14.04 — a potential gain of +290% from today's $3.60. That is up +12% on the projected 2035 average. Momentum favours further upside here.
SAB Biotherapeutics, Inc.'s 2050 outlook centres on $37.22, within a $17.03 to $78.25 range. That is up +165% on the projected 2040 average. That marks a +934% change versus current levels. Buyers look set to stay in control over this stretch.
Investing $1,000 in SABS today (≈ 277.777778 SABS) could be worth
$10,337.64
+$9,337.64 (+934%) by 2050 · US Dollar
Based on the average projected SABS price of $37.22 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in SABSwould be worth at today's price.
$1,000 invested in SABS on May 27, 2025 (≈ 561.797762 SABS) would be worth
$2,022.47
+$1,022.47 (+102.2%) today · 2.02× · US Dollar
Based on a SABS entry price of $1.78 vs. today's $3.6.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $3.68 | $978.26 | -2.2% |
| 1 month ago | $3.47 | $1,037.46 | +3.7% |
| 3 months ago | $4.13 | $871.67 | -12.8% |
| 6 months ago | $3.95 | $911.39 | -8.9% |
| 1 year ago | $1.78 | $2,022.47 | +102.2% |
| All time (5.0y) ago | $99.2 | $36.29 | -96.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our SABS forecast.
Our base-case forecast reaches $7.20 around 2030.
Implied market cap at $7.20: $550.54M
The multi-year forecast shows a steady upward trajectory in the average price, with key milestones including 2026 avg $3.60 and 2030 avg $7.27 (ROI 102) and continuing to 2050 avg $37.22 (ROI 933.8). The 2040 forecast suggests an avg of $14.04 (ROI 289.9) and the 2035 forecast at an avg of $12.56 (ROI 248.9), reflecting a bullish long-term outlook across the horizon. While these figures indicate substantial upside, they remain estimates and are not guarantees, with sentiment remaining bullish across the forecast years.
Tap a question to reveal the answer.
2030 min $5.03, avg $7.27, max $11.40 with ROI 102 and sentiment BULLISH.
Forecasts show a bullish trajectory with rising averages in later years (e.g., 2027 avg $5.10, 2030 avg $7.27, 2050 avg $37.22) and bullish sentiment in multiple years, but these are estimates and not guarantees.
Yes. The forecast includes a 2035 max of $21.96 and a 2040 max of $26.48, indicating a $20 level could be reached in the forecast horizon.
Current price is $3.60 and market cap is $275.27M, with a rank of 3557.
2050 avg $37.22 with a max of $78.25 and ROI 933.8, supported by a bullish sentiment.
SAB Biotherapeutics, Inc. Community Discussion
0Share your SAB Biotherapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.